Knight Therapeutics (TSE:GUD) has released an update.
Knight Therapeutics Inc. has reported a 5% revenue growth to $86.6 million in the first quarter of 2024, driven by key product sales but offset by a 25% decrease in adjusted EBITDA due to higher marketing expenses for new product launches. Despite the net loss widening slightly from the previous year, the company saw a substantial 616% increase in cash flow from operations due to strong operating results and improved working capital management. The company has also expanded its portfolio with the launch of new products in Canada and Brazil, and by in-licensing and regulatory approvals in Latin America.
For further insights into TSE:GUD stock, check out TipRanks’ Stock Analysis page.
